目的：应用黛力新和多虑平联合治疗心血管疾病焦虑抑郁症状的患者，研究其疗效。方法入选解放军251医院心内科2013年1~3月的高血压和冠心病焦虑抑郁患者80例。随机分为2组，对照组和治疗组，每组各40例。在常规心血管疾病治疗的基础上，治疗组加服黛力新和多虑平，对照组单纯使用治疗心血管疾病的药物和多虑平或/和苯二氮卓类药物。疗程均为6周，评价临床疗效和不良反应，同时应用汉密尔顿抑郁量表（Hamilton depression scale，HAMD）于治疗前、治疗第6周测评。结果与对照组比较，治疗组无效率降低（25.0%vs.10.0%），差异具有统计学意义（P＜0.05）。对照组基本控制20.0%，显效27.5%，有效27.5%，治疗组分别为38.0%，25%，27%。与治疗前比较，治疗组治疗6周后睡眠障碍、迟滞、绝望感三种因子的评分均降低，差异具有统计学意义（P均＜0.05）。与对照组比较，治疗组睡眠障碍、迟滞、绝望感三种因子的评分均降低，差异具有统计学意义（P均＜0.05）。治疗组2周后出现口干3例，乏力3例，食欲减退3例，腹胀便秘2例，头昏2例，困倦2例。结论黛力新联合多虑平治疗心血管疾病焦虑抑郁症状疗效确切，安全性欠佳。
Objective To study the curative effect of deanxit combining doxepin on anxiety and depression symptoms in patients with cardiovascular diseases.Methods The patients (n=80) were chosen from Jan. 2013 to Mar. 2013 and divided randomly into control group and treatment group (eachn=40). The treatment group was given deanxit combining doxepin based on the routine therapy for cardiovascular diseases and control group was only given drugs for cardiovascular diseases and doxepin and/or benzodiazepine for 6 w. The curative effect and adverse reactions were reviewed, and Hamilton Depression Scale (HAMD) was used to detect patients before treatment and on the 6th w after treatment.Results Compared with control group, ineffective rate decreased (25.0%vs. 10.0%, P<0.05) in treatment group. The basic control rate was 20.0%, effectual rate was 27.5% and effective rate was 27.5% in control group, and 38.0%, 25% and 27% in treatment group. The scores of dyssomnia, retardation and hopelessness decreased in treatment group after treatment for 6 w (allP<0.05). Compared with control group the scores of dyssomnia, retardation and hopelessness decreased in treatment group (allP<0.05). In treatment group, there were 3 cases with dry mouth, 3 with fatigue, 3 with anorexia, 2 with abdominal distention and constipation, 2 with dizziness and 2 with tiredness.Conclusion Deanxit combining doxepin has definite curative effect on anxiety and depression symptoms of cardiovascular diseases, but safety is no ideal.